Title
Administration of protein-conjugate pneumococcal vaccine to patients who have invasive disease after splenectomy despite their having received 23-valent pneumococcal polysaccharide vaccine
Date Issued
01 April 2005
Access level
open access
Resource Type
journal article
Author(s)
Musher D.
Ceasar H.
Kojic E.
Musher B.
Gathe J.
Romero-Steiner S.
Baylor College of Medicine
Abstract
Patients who undergo splenectomy are at greatly increased risk for overwhelming pneumococcal bacteremia and death. Twenty-three-valent pneumococcal polysaccharide vaccine (PPV-23), which contains capsular polysaccharides (PSs) from 23 common serotypes of Streptococcus pneumonias, is strongly recommended for such patients. The capacity to respond to PPV-23 by producing immunoglobulin (Ig) G is genetically regulated. Some proportion of adults do not respond and, despite postsplenectomy administration of PPV-23, may remain susceptible to recurrent pneumococcal sepsis. Here, we describe 2 patients who had recurring pneumococcal bacteremia after undergoing splenectomy despite having received numerous doses of PPV-23. Heptavalent protein-conjugate pneumococcal vaccine (PCPV-7) was then administered, and it induced high levels of IgG to all 7 PSs; in one of the patients, functional activity against 5 of the 7 PSs was demonstrable, both in vitro and in vivo. Recurrent pneumococcal bacteremia in patients who have undergone splenectomy may indicate a genetically regulated failure to respond to PPV-23; PCPV-7 may stimulate production of IgG to PSs in such patients. © 2005 by the Infectious Diseases Society of America. All rights reserved.
Start page
1063
End page
1067
Volume
191
Issue
7
Language
English
OCDE Knowledge area
Hematología Inmunología
Scopus EID
2-s2.0-15544375526
PubMed ID
Source
Journal of Infectious Diseases
ISSN of the container
00221899
Sources of information: Directorio de Producción Científica Scopus